Spain, June 30 -- Spain based JANSSEN-CILAG, S.A. has secured contract from Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad for Antivirals for systemic use - Centralized acquisition and supply of environmentally friendly medicines for human use containing the following active ingredients: bulevirtide, cabotegravir, dolutegravir and different combinations with this active ingredient, rilpivirine, darunavir/cobicistat, etravirine, rilpivirine and nirmatrelvir/ritonavir . The value of the contract is not disclosed .
Published by HT Digital Content Services with permission from Pivotal Sources....